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were included. 68 foci were found in 58 women [34.9 %, 
95 % confidence interval (CI) 28.1–42.5 %]. Foci were 
more frequent in dense breasts (P = 0.079) and with mod-
erate or marked BPE (P < 0.001). During follow-up, two 
foci increased in size (2.9 %, 95 % CI 0.8–10.1 %) and at 
biopsy, a cancer was found (1 high-grade ductal carcinoma 
in situ, 1 tubular carcinoma). Breast cancer was diagnosed 
in the other three cases, not initially appearing as foci, 
and it was more frequent in women with dense breasts 
(P = 0.04); no correlation between cancer and BPE was 
found (P = 0.145).
Conclusions Foci are relatively frequent in screening MRI, 
and they are usually benign. An increase in size is the most 
reliable criteria to suspect malignancy.
Keywords Breast · Magnetic resonance imaging · 
BI-RADS · High-risk · Cancer
Introduction
High-risk women present a lifetime risk of developing 
breast cancer higher than 20 % [1]. This increased risk is 
related to several factors, the more relevant being: the pres-
ence of a gene mutation (BRCA 1 and BRCA 2 being the 
more common), family history of breast or ovarian cancer 
(the first-degree relatives, with an early onset of the dis-
ease) [1, 2]. Malignant lesions found in these women are 
characterized by an early onset and by a high proliferation 
rate, thus being often more aggressive, as compared to the 
cancer usually diagnosed in the general population [3, 4].
In consideration of this evidence, various dedicated 
screening programs have been developed to allow early 
diagnosis in high-risk patients. These programs start at a 
young age, usually 30 years old or as soon as the risk factor 
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Purpose To assess how frequently foci are identified 
on MRI in high-risk patients, and their association with 
malignancy, breast density, and background parenchymal 
enhancement (BPE).
Materials and methods In this multicentric study, two 
readers, in consensus, retrospectively reviewed screening 
breast MRI of 245 high-risk women, performed between 
2009 and 2014. Eligible patients had at least two consecu-
tive screening MRI, and a follow-up of at least 1 year after 
a lesion was first detected; histology was available for all 
suspicious findings. Breast density, BPE (both using BI-
RADS lexicon), presence, and changes at follow-up for 
foci were evaluated. Clinical history of the patients was 
reviewed. Chi-square test was used to define significant 
correlations.
Results 166 women (mean age 43 years), who underwent 
a median of 4 MRI (range 2–6) during the study period, 
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is found. Along with the traditional imaging modalities, 
such as mammography and ultrasound, breast magnetic 
resonance imaging (MRI) plays a central role [1, 5]. Breast 
MRI has the highest sensitivity in breast cancer detection 
[6]; several multicentric studies proved that MRI, com-
pared to mammography and ultrasound, is able to identify 
a higher number of cancers and at an earlier stage [7–10].
MRI is also able to detect very small enhancing lesions, 
with 5 mm or lower maximum diameter, which might be 
difficult to further characterize. These small lesions are 
defined by the American College of Radiology Breast 
Imaging Reporting and Data System (ACR BI-RADS) as 
foci. A focus is a small dot of enhancement that stands out 
from parenchymal enhancement. Per definition, foci cannot 
be accurately assessed with respect to margin or internal 
enhancement: if these characteristics can be assessed, the 
finding should be considered a small mass [11]. Foci are 
frequently associated with an increased hormonal stimula-
tion, and they can sometimes be seen when a benign lesion 
is present (fibroadenoma, cyst and fibrocystic changes, 
lymph node), but they can also represent the early onset of 
a malignant lesion [12, 13]. Studies addressing the malig-
nancy rate of foci found in the general population showed 
highly variable results, with percentages ranging from 0.6 
to 23 % [12, 14]. Thus, the best management of foci is 
still under discussion. The issue is of particular interest in 
high-risk women, especially considering the importance of 
early diagnosis in this group of patients. Despite this, not 
many studies addressed the frequency of foci detected dur-
ing screening MRI in high-risk patients and the malignancy 
rate of foci in this population.
The aim of our study was to determine how frequently 
foci are identified on breast MRI in high-risk patients, and 
how frequently foci are found to be malignant. We further 
correlated the presence of foci and malignancy with breast 
density and background parenchymal enhancement.
Materials and methods
Patients’ collection
This retrospective study involved two institutes, both 
with dedicated breast units. Patients included gave their 
informed consent in both centres, and IRB approval was 
granted. In both institutions, women with family history of 
breast and ovarian cancer (more than one close relative, at a 
young age) are sent to genetic counselling. The risk and the 
likelihood of detecting a pathogenic gene change are cal-
culated using a standard risk assessment modality (such as 
CaGene), and when deemed necessary, the patient under-
goes genetic testing.
Screening is performed with annual breast MRI and 
ultrasound; digital mammography is performed annually in 
women older than 35 years. All breast MRIs performed for 
screening in high-risk women between January 2009 and 
October 2014 were reviewed.
Patients were included in this retrospective analysis 
when: at least two rounds of MRI screening were avail-
able; at least 1 year follow-up was available after a focus 
was detected for the first time; histological verification or 
follow-up of at least 1 year for all findings classified as BI-
RADS 3 or higher was available. Cases that did not meet 
the inclusion criteria, incomplete MRI examinations, cases 
with previous bilateral mastectomy, and cases for which 
information about risk factors was not available, were 
excluded.
The high-risk databases of the two institutions were 
reviewed to collect data on gene mutation and family his-
tory for the included patients. A total of 245 high-risk 
women were retrieved, and 169 met the inclusion criteria. 
Age at the time of first examination ranged between 23 and 
68 years old (mean 43.6 years old).
Breast MRI acquisition
In both the institutes, breast MRI was performed according 
to the guidelines defined by the EUSOMA working group 
[15], on 1.5-T magnet (Magentom Avanto, Siemens, Erlan-
gen, Germany in both institutes), using vendor-supplied 
dedicated bilateral breast coils (four channels). Exami-
nations were performed with patient in the prone posi-
tion, among the 7th and 14th day of the menstrual cycle 
for pre-menopausal women. The standard protocol used 
for the clinical evaluation consisted of an axial Short-Tau 
Inversion Recovery (STIR) T2-weighted sequence and an 
axial spoiled Gradient-Echo 3D (FLASH) T1-weighted 
sequence acquired before and five times after the injec-
tion of contrast material for the dynamic study (Gado-
benate Dimeglumine, Multihance, Bracco; 0.01 mmol/kg 
of body weight, injected at the rate of 2 ml/s, followed by 
a flush of 20 ml of saline solution). Technical parameters 
of the T1-weighted fast low-angle shot sequences were: 
TR 9 ms, TE 4.76 ms, FOV 340 × 340 mm, slice thickness 
2 mm, matrix 512 × 512 at one institution; and 7.4, 4.7 ms, 
340 × 340 mm, 1.3 mm, 384 × 369 at the other institution. 
Starting from 2012, an axial echo-planar imaging (EPI) dif-
fusion-weighted sequence was also acquired.
Image analysis
Two readers with more than 3 years of experience in breast 
imaging and breast MRI reviewed the images in consen-
sus. Readers were aware of the indication for the MRI 
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(screening), but they were blinded to the number and type 
of lesions present in the data set.
For each MRI examination, readers had to evaluate pres-
ence or absence or foci. The BI-RADS definition of a focus 
was strictly followed [11], and lesions that could be further 
characterized by evaluating pre- and post-contrast T1w 
sequences, T2w sequences, or DWI were not considered, 
even when presenting a diameter equal or lower to 5 mm 
(i.e., cysts, small spiculated masses, and lymph nodes). In 
patients showing strong, punctate, background enhance-
ment, a focus was described only when showing enhanc-
ing characteristics clearly different from that of the remain-
ing fibroglandular tissue. For all detected foci, readers 
had to state whether in the subsequent examinations, the 
lesion was disappearing, reducing in size, stable, increas-
ing in size, or showed any change in morphology sug-
gesting malignancy. Number of foci per patient was also 
considered.
Breast density was evaluated on pre-contrast T1w 
sequences and classified according to the BI-RADS lexi-
con: (a) almost entirely fat; (b) scattered fibroglandular 
tissue; (c) heterogeneous fibroglandular tissue; and (d) 
extreme fibroglandular tissue. Pattern of background paren-
chymal enhancement (BPE) was defined on the post-con-
trast study, according to the BI-RADS lexicon: (a) mini-
mal; (b) mild; (c) moderate; and (d) marked.
Statistical analysis
Overall number of newly appearing foci was calculated. 
Malignancy rate for foci was calculated as number of breast 
cancers initially appearing as foci as compared to overall 
number of foci. Proportions are presented as percentages 
with 95 % confidence interval (95 % CI).
The relation between presence of foci in patients with 
different breast densities or in MRI with different BPEs 
was evaluated using the Chi-square test.
Finally, the presence of malignant lesions was compared 
in patients with or without foci, and considering breast 
density and BPE, using the Chi-square test. Analysis was 
performed using the statistical software commercially 
available (MedCalc Software v.20, Ostend, Belgium).
Results
Three patients were excluded from the evaluation, because 
a malignant lesion was diagnosed during the first MRI 
examination.
Overall, 166 patients were included, and 640 MRI 
examinations were performed, with a median of four exam-
ination per patient (range 2–6 examinations).
Of these 166 patients: 100 had a known pathologic muta-
tion (46 BRCA 1, 52 BRCA 2, 1 BRCA 1 and 2, 1 p53); 17 
were tested and the results were negative for BRCA1 and 
BRCA2 mutations (BRCAX); and 49 had a calculated risk 
superior to 20 %, but were not tested or results were not 
available at the time of data collection.
At least one focus was detected in 52/166 (31.3 %, 95 % 
CI 24.8–38.7 %) patients during the first MRI examination 
and in other six patients (3.6 %) in a subsequent examina-
tion, overall foci were found in 58/166 patients (34.9 %, 
95 % CI 28.1–42.5 %). A single focus was found in 50 
patients (86.2 %, 95 % CI 75.1–92.8 %), while two or more 
foci were detected in the remaining eight patients (13.8 %, 
95 % CI 7.2–24.9 %). Overall, 68 foci were detected. 
When considering separately each MRI, one or more focus 
was detected in 215/640 examinations (33.6 %, 95 % CI 
30.0–37.3 %).
During follow-up, the majority of the foci were stable: 
57 foci showed no changes in dimensions or morphology 
(83.8 %, 95 % CI 73.3–90.7 %). Nine foci disappeared dur-
ing follow-up (13.2 %, 95 % CI 7.1–23.3 %), 1 or 2 years 
after the examinations where they were first detected. In 
none of the cases, a reduction in size was clearly visible.
One focus (1.5 %) in a BRCA 2 mutate woman, after 
1 year, increased from 5 to 10 mm, and showed also altera-
tions in the morphology, appearing as a non-mass lesion 
(Fig. 1). One focus (1.5 %) in a non-tested woman with a 
strong family history increased from 5 to 15 mm at 1 year 
Fig. 1  A small focus was 
detected in the central area of 
the left breast in a screening 
MRI performed in a 46-year-old 
woman (a, arrow). The finding 
was considered non suspicious 
and the patient was sent to 
1-year control. After 1 year (b, 
arrow), the area increased in 
size and MR-guided biopsy was 
performed. Histology showed 
a high-grade ductal carcinoma 
in situ
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follow-up. Also in this case, a slight modification in mor-
phology was found, and a mass lesion on T1-weighted 
sequences could be seen (Fig. 2). In both the cases, the 
lesion was biopsied and histology was high-grade ductal 
carcinoma in situ and tubular carcinoma, respectively. 
Malignancy rate for foci was 2.9 % (2 on 68, 95 % CI 
0.8–10.1 %).
Other three cancers were found during the study period 
in one BRCA 2 patient and in two non-tested patients: two 
invasive ductal carcinomas and one high-grade ductal car-
cinoma in situ. Two high-risk lesions were also detected 
in other two patients: one phyllodes tumour and one atypi-
cal ductal hyperplasia. Neither the other cancers nor the 
high-risk lesions initially appeared as a focus. Overall, 2 
on 5 cancers detected during the study period (40 %) were 
initially visible as foci, without any further suspicious 
characteristic.
Breast density distribution and distribution of foci and 
malignancy in the various density classes are shown in 
Table 1. No significant difference in the distribution of foci 
was found (P = 0.079, Fig. 3), though a trend towards a 
higher percentage of foci in dense breast was detected. 
A significantly higher number of cancers were detected 
in patients with dense breasts compared to those with 
non-dense breasts (P = 0.04). A similar result was obtained 
when considering both cancers and high-risk lesions 
(P = 0.03).
Fig. 2  A small focus was detected in the retroareolar region of the 
left breast in a screening MRI performed in a 62-year-old woman (a, 
arrow). The finding was considered non suspicious and the patient 
was sent to 1-year control. After 1 year (b, arrow), the patient came 
at the control with nipple retraction. A retroareolar mass enhancement 
was found, and a biopsy was performed under the U.S. guidance after 
the second-look ultrasound. Histology showed a tubular carcinoma
Table 1  Number of patients presenting with foci, number of foci, 
and cancer cases according to breast density distribution
Percentages are given in brackets
Breast density Patients with foci Foci Cancer cases
Single focus Multiple foci N N
a = 36 7 (19.4) 0 (0.0) 7 0
b = 36 13 (36.1) 1 (2.8) 15 1
c = 55 19 (34.5) 2 (3.6) 24 4
d = 39 11 (28.2) 5 (12.8) 22 0
Fig. 3  Distribution of foci according to breast density, classified 
using the BI-RADS lexicon
Table 2  Number of foci and cancer cases according to background 
parenchymal enhancement distribution




a = 458 151 (32.9) 2
b = 117 57 (48.7) 3
c = 44 35 (79.5) 0
d = 21 7 (33.3) 0
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Distribution of BPE, foci, and malignant lesions is 
shown in Table 2.
Foci were more frequently encountered when BPE was 
present (P < 0.001), and this significant difference was 
confirmed also when comparing low (a and b) with high (c 
and d) levels of BPE (P < 0.001, Fig. 4). There was no dif-
ference in cancer distribution related to BPE (P = 0.145), 
and the same was found when considering also high-risk 
lesions (P = 0.328).
Discussion
We identified foci in one-third of breast MRI screening 
examinations performed during a 5-year period in high-
risk patients. Only in the two cases, these small areas of 
non-specific enhancement were found, at follow-up, to be 
malignant lesions (2.9 %). Malignancy was more frequent 
in dense breasts, but no correlation with BPE was found.
Foci on breast MRI can be associated with hormonal 
stimulation or with a wide variety of findings, being most 
often related to benign proliferative or non-proliferative 
changes of the breast, cysts, or small lymph nodes. Rarely, 
they might represent an early sign of malignancy.
Foci were detected in a higher number of patients, as 
compared to other studies [14, 16]. This difference might 
have various explanations: high number of young patients 
with dense breast, thus with a higher hormonal stimulation, 
the different definitions of focus used in different stud-
ies, and the different acquisition parameters and thus dif-
ferent capabilities of distinguish a true focus from a small 
lesion. Of note, we obtained a malignancy rate well within 
the lower limits of the range presented in the literature for 
the general population [12, 14]. There is a significant vari-
ability regarding the malignancy rate of foci (from 0.6 to 
23 %) [12–14, 17–21]. This high variability can have vari-
ous explanations the more relevant being case selection 
and the definition of focus. In some studies [14, 21, 22], 
lesions visible on pre-contrast T1w or T2w sequences, and 
thus amenable of further characterization, were classified 
as foci on the basis of their maximum diameter. According 
to the latter BI-RADS definition [11], this category of MRI 
findings was excluded from our analysis. The highest spa-
tial resolution achievable with new sequences and higher 
field strengths allows obtaining more details on lesions 
characteristics, and it is mandatory to carefully evaluate the 
small areas of enhancement in all sequences, as important 
diagnostic information can be detected [23].
Liberman et al. [12] analysed a small group of high-risk 
patients and found a similar percentage of malignancy in 
their evaluation, also not different from the malignancy rate 
of the general population.
Management of foci is still a topic of discussion. 
According to most of the literature, foci might represent 
cancer in more than 2–3 % of the cases, and thus in specific 
single cases, (synchronous breast malignancy, patients’ 
decision) biopsy should be considered [24]. On the other 
hand, it is highly unlike that the decision to biopsy all foci 
would be cost-effective, as in most of the cases, biopsy 
can only be performed under MR-guidance and the major-
ity of the lesions will turn out to be benign [17, 24]. The 
only sign on which various studies agree to define a focus 
as suspicious is the increase in size [24]; thus, indication 
for biopsy should be given only when an increased focus 
is found. Furthermore, modification in the appearance of 
the focus, related or not to a modification in size, should be 
considered suspicious and indicate the need for a biopsy. 
In both our cases, cancers detected showed a minimal 
growth at follow-up after 1 year. As 6 months control was 
not performed, it is not possible to state whether it would 
have allowed an earlier diagnosis. Short-term follow-up 
could help in the earlier detection of lesions increasing in 
size but, on the other hand, a small increase might be unde-
tected when performing a short-term evaluation. Of note, 2 
on 5 cancer diagnosed were initially visible as a focus, thus 
suggesting the need to identify more features helpful in the 
early characterization of foci.
Though not many data are available on the effect of BPE 
on lesion identification on MRI, it is likely that benign pro-
liferative changes in the breast can be associated to both 
foci and BPE [25].
Fig. 4  Distribution of foci according to breast background parenchy-
mal enhancement (BPE), in patients with minimal or mild BPE (ACR 
BI-RADS a, b) and moderate or marked BPE (ACR BI-RADS c, d)
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Several studies already showed the importance of breast 
density as a risk factor for breast cancer [26], and these 
were also seen in our study. A recent study [27] found a 
correlation between BPE and cancer risk, but this was 
not confirmed by our results. The relatively small number 
of cases included in our analysis might have limited this 
evaluation.
Our study has some limitations: though two centres were 
involved, the overall number of foci and cancer detected 
was not high and it is not possible to draw conclusions on 
management. In addition, though average follow-up was 
4 years, many patients underwent only a 2-year follow-
up. Especially in the beginning of the study period, several 
patients were lost at follow-up or did not agree to partici-
pate in the study. We believe this was strongly related to 
poor patients’ awareness and scarce implementation of 
structured national screening programs. Increased informa-
tion to patients and more structured programs can improve 
women’s compliance to MRI screening. An overall small 
number of cancers were found during the analysed period. 
We believe that this result is mainly related to our case 
selection: some cancer cases were not included in the 
study, as not enough follow-up was available. Furthermore, 
three patients initially included in the analysis were then 
excluded as cancer was diagnosed at the first examination. 
These patients were excluded as the modifications related 
to the therapy might have affected image interpretation.
In conclusion, we found that foci are a relatively fre-
quent finding in screening breast MRI performed in high-
risk women, but they are rarely related to malignancy. 
Malignant lesions were more frequent in women with 
dense breast, while no relation with background parenchy-
mal enhancement was found. Malignancy rate of foci does 
not seem to be higher, as compared to the general popula-
tion, thus suggesting that the same management could be 
adopted. When a focus increases in size, or shows suspi-
cious imaging characteristics, biopsy must always be per-
formed. Whether the best management of a newly detected 
focus is biopsy, short-term follow-up or 1-year follow-up is 
still under discussion; and further studies will be necessary 
to clarify this issue.
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